Key facts
- This page summarizes Kimi Iguchi's Form 4 filing for Sage Therapeutics, Inc. (SAGE).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 05 Jan 2023, 15:30.
Kimi Iguchi - 04 Jan 2023 Form 4 Insider Report for Sage Therapeutics, Inc. (SAGE)
- Reporting relationship
- CFO & Treasurer
- Issuer ticker
- SAGE
- Reported as of
- 04 Jan 2023
- Net transaction value
- +$2,448
- SEC form
- 4
- Accepted by SEC
- 05 Jan 2023, 15:30:11 UTC
- Prior SEC filing
- 18 Feb 2022
- Next SEC filing
- 11 Jan 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jennifer Fitzpatrick, as Attorney-in-Fact for Kimi Iguchi
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Kimi Iguchi filed Form 4 for Sage Therapeutics, Inc. (SAGE) on 05 Jan 2023.
Change
- Previous filing in this sequence was filed on 18 Feb 2022.
- Current net transaction value: +$2,448.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SAGE
transaction
Common Stock
Options Exercise
- Transaction value
- $2,448
- Shares
- +1,800
- Change %
- +3.2%
- Price
- $1.36
- Shares after
- 58,024
- Date
- 04 Jan 2023
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SAGE
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -1,800
- Change %
- -20%
- Price
- $0.000000
- Shares after
- 7,242
- Date
- 04 Jan 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,800
- Exercise price
- $1.36
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Reflects beneficial ownership balance which includes 427 shares purchased on June 30, 2022 and 197 shares purchased on December 31, 2022, each under the Sage Therapeutics, Inc. 2014 Employee Stock Purchase Plan.
Footnote F2
The stock option award was issued pursuant to the Sage Therapeutics, Inc. 2011 Stock Option and Incentive Plan. The option vested in full on July 23, 2016.